COMPANY PROFILE

Artera

Explore full profile

AI-enabled cancer therapy personalization

Menlo Park, United StatesFounded 2022Health Tech & Medtech

Valuation $100–500M Latest valuation · 2025

Revenue $100–500M Latest reported FY

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Artera

Artera.ai is a cutting-edge startup operating in the healthcare technology sector, specifically focusing on the personalization of prostate cancer therapy. Utilizing advanced multi-modal deep learning techniques, Artera.ai is revolutionizing the way prostate cancer treatment is approached. Their primary offering is the ArteraAI Prostate Test, a high complexity clinical laboratory test developed in-house. This test is not experimental but is used for actual clinical purposes, indicating a high level of reliability and effectiveness.

Read full description

Artera.ai's business model is centered around the provision of this test to healthcare providers and patients. By offering a more personalized approach to prostate cancer therapy, Artera.ai is able to provide a unique value proposition in the market. The company operates in the broader healthcare and medical technology market, serving clients such as hospitals, clinics, and individual patients.

The company generates revenue through the sale of their ArteraAI Prostate Test. Their technology is based on randomized phase III clinical trials, which are the final stage of testing before a new treatment is approved for public use. This indicates a high level of scientific rigor and reliability in their product.

Artera.ai is also committed to continuous learning and improvement, as evidenced by their regular publications and news updates. They are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), further reinforcing their credibility in the field.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Menlo Park, United States
Employees: 148
Open positions: 4
Dealroom signal: 91.7/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Oncology, Core AI, Spinout, Clinical Decision Support, Tech for Medical Professionals, AI Applications, DT and LS, science-based
Technology: Artificial Intelligence, Deep Tech
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Artera.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Dec 2025	$65M	$450M	Health Velocity Capital · Jackson Square Ventures · Summation Health Ventures · Heritage Medical Systems	↗
EARLY VCOther financing	Nov 2023	$20M	$450M	Prosperity7 Ventures · Andrew Tan. · EDBI · Wilson Sonsini	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Artera website traffic

Latest recorded traffic for Artera is 17K monthly website visits, up 30.8% over the last three months. Artera's team grew 10.4% over the past year.

Latest monthly visits17K 3-month web change+30.8% 1-year team growth+10.4%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Sales Account Executive (Virginia/West Virginia)Richmond, Virginia, United States, Northern America, Americas · Sales · Aug 5, 2026 Biostatistics Research AssociateOttawa, Ontario, Canada, Northern America, Americas · Other · Jul 17, 2026 Sales Account Executive (Chicago)Chicago, Illinois, United States, Northern America, Americas · Sales · Jun 30, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OPOptellumDeveloping an artificial intelligence software platform to support clinicians in lung cancer nodule management	Oxford, United Kingdom	Operational	51	$30M	$23M
KTKheiron Medical TechnologiesHelps radiologists detect breast cancer earlier using deep learning	London, United Kingdom	Acquired
THTherapixelSoftware company specialized in artificial intelligence for medical image analytics	Paris, France	Operational
VIVisiopharmAI-driven precision pathology and tissue image analysis software	Hørsholm, Denmark	Acquired
NANucs AIAdvanced AI-driven solutions that deliver precise, actionable insights for the clinical management of prostate cancer, empowering healthcare professionals	San Francisco, United States	Operational
INIntelligynBuilding the future of gynecological diagnostics with advanced AI technology for accurate and equal care, everywhere	Stockholms kommun, Sweden	Operational
SUSurgeInnovative fingerprinting of the immune system with AI to holistically improve the perioperative standard-of-care	Paris, France	Operational
HAHarrison.aiClinician-led healthcare artificial intelligence company that innovates efficient and accessible solutions and services. Creates AI-as-a-medical device solutions that have a global impact and support clinical excellence	Sydney, Australia	Operational